• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6,366
2,300
1,861
1,850
1,725

COUNTRY

868
650
270
253
211

CATEGORIES

  • 858
  • 186
  • 679
  • 1,126
  • 391
  • 270
  • 255
  • 65
  • 379
  • 693
  • 1,330
  • 1,355
  • 625
  • 884
  • 1,695
  • 2,677
  • 507
  • 732
  • 0
  • 93

PRICE

7,153
12,253
18,302
25,176

PUBLISHED

1,686
2,623
7,174
25,176

PRODUCT TYPE

21,051
2,901
873
164
75
44
21
21
19
6
1

Pharmaceuticals

The pharmaceutical industry has been for decades one of the most profitable worldwide. Serious challenges, such as the expiry of long-term lucrative patents (Lipitor, to mention just one) and the cuts in healthcare and R&D in many countries worldwide, can pose a challenge to the growth of the industry. Which drug can save the life of the pharmaceutical industry? Highly differentiated strategies: this is what companies should focus on now if they want to stay competitive. Do you want to know more?

You can get a detailed picture of the market and refine your marketing, brand, and sales strategies with the reliable, up-to-date business information provided by the extensive range of reports, books and subscriptions listed under Research and Markets’ Pharmaceuticals category. They cover markets, companies (big Pharma, mid-sized specialty pharmaceutical companies, generic manufacturers, and small firms), technologies, e-healthcare, pharmaeconomics, drug discovery, and drug delivery.

The product coverage is huge. It includes OTC drugs as well disorder and goal-specific products related to respiration, oncology, vitamins, cardio, analgesics, central nervous system, generics, immune disorders, and women’s health. Show Less
Read more

PRODUCT TITLE

PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022

“PharmaPoint: Chronic Heart Failure - France Drug Forecast and Market Analysis to 2022” The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and...

June 2013
FROM

PharmaPoint: Chronic Heart Failure - Japan Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Heart Failure - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Heart Failure - Japan Drug Forecast...

June 2013
FROM

Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review, H1, 2013

Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review, H1, 2013 Summary This clinical trial report, “Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review,...

June 2013
FROM

Avastin (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

Avastin (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players

PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players”. The...

June 2013
FROM

LDK378 (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022

LDK378 (Non-Small Cell Lung Cancer) - Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women....

June 2013
FROM

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - UK Drug Forecast and Market Analysis to 2022 Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and...

June 2013
FROM

Ablynx NV - Product Pipeline Review - 2013

Ablynx NV - Product Pipeline Review - 2013 Summary “Ablynx NV - Product Pipeline Review - 2013” provides data on the Ablynx NV’s research and development focus. The report includes information...

June 2013
FROM

Spinocerebellar Ataxias - Pipeline Review, H1 2013

Spinocerebellar Ataxias - Pipeline Review, H1 2013 Summary 'Spinocerebellar Ataxias - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

June 2013
FROM

Retinal Degeneration - Pipeline Review, H1 2013

Retinal Degeneration - Pipeline Review, H1 2013 Summary 'Retinal Degeneration - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM

Traveler's Diarrhea - Pipeline Review, H1 2013

Traveler's Diarrhea - Pipeline Review, H1 2013 Summary 'Traveler's Diarrhea - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

June 2013
FROM

Seizures - Pipeline Review, H1 2013

Seizures - Pipeline Review, H1 2013 Summary 'Seizures - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic...

June 2013
FROM

Corneal Neovascularization - Pipeline Review, H1 2013

Corneal Neovascularization - Pipeline Review, H1 2013 Summary 'Corneal Neovascularization - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

June 2013
FROM

Laboratoris Sanifit S.L. - Product Pipeline Review - 2013

Laboratoris Sanifit S.L. - Product Pipeline Review - 2013 Summary “Laboratoris Sanifit S.L. - Product Pipeline Review - 2013” provides data on the Laboratoris Sanifit S.L.’s research and development...

June 2013
FROM

M's Science Corporation - Product Pipeline Review - 2013

M's Science Corporation - Product Pipeline Review - 2013 Summary “M's Science Corporation - Product Pipeline Review - 2013” provides data on the M's Science Corporation’s research and development...

June 2013
FROM

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2013

Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2013 Summary 'Cerebral Infarction (Brain Infarction) - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

June 2013
FROM

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013

Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H1 2013 Summary 'Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus...

June 2013
FROM

Pain Therapeutics, Inc. - Product Pipeline Review - 2013

Pain Therapeutics, Inc. - Product Pipeline Review - 2013 Summary “Pain Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Pain Therapeutics, Inc.’s research and development...

June 2013
FROM

Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2013

Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2013 Summary “Alder Biopharmaceuticals Inc. - Product Pipeline Review - 2013” provides data on the Alder Biopharmaceuticals Inc.’s research...

June 2013
FROM

Laboratorios SALVAT S.A. - Product Pipeline Review - 2013

Laboratorios SALVAT S.A. - Product Pipeline Review - 2013 Summary “Laboratorios SALVAT S.A. - Product Pipeline Review - 2013” provides data on the Laboratorios SALVAT S.A.’s research and development...

June 2013
FROM
Loading Indicator

Our Clients

Our clients' logos